ISRCTN06697555已完成未知
A prospective, active control open label, multicentre randomized clinical trial for comparison between BioMime Sirolimus Eluting Stent of Meril Life Sciences Pvt.Ltd. and Xience Xpedition Everolimus Eluting stent of Abbott Vascular Inc. to evaluate efficacy and safety in Coronary Artery Disease
Meril Life Sciences Pvt. Ltd. (India)0 个研究点目标入组 256 人开始时间: 2014年4月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 256
研究概览
简要总结
2018 results in: https://www.ncbi.nlm.nih.gov/pubmed/30222120 (added 07/08/2019)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. The patient must be =18 years of age.
- •2. Clinical evidence of ischemic heart disease and/or a positive territorial functional study. Documented stable angina pectoris (Canadian Cardiovascular Society (CCS) Classification 1, 2, 3 or 4) or unstable angina pectoris with documented ischemia (Braunwald Class IB-C, IIB-C, or IIIB-C), or documented silent ischemia
- •3. The patient has a planned intervention of up to two de-novo native lesions
- •4. Target lesion reference diameter = 2.5 mm and = 3.5 mm in diameter (visually estimated)
- •5.The target lesion length is less than or equal to 46 mm (visually estimated)
- •6. Patient willing to provide written informed consent.
- •7. If the patient is a female, she should be without childbearing potential who has undergone surgical sterilization or is post-menopausal.
- •8. The patient and the patient?s physician agree to the follow-up visits including a 9 month angiographic follow-up.
排除标准
- •1. Evidence of an acute Q-wave or non-Q-wave myocardial infarction within 72 hours preceding the index procedure, unless the CK and CK-MB enzymes are less than twice the Upper Normal Limit.
- •2. The patient has a known hypersensitivity or contraindication to any of the requisite medications including aspirin, heparin, clopidogrel, prasugrel, ticagrelor, sirolimus, everolimus.
- •3. There is an untreated significant lesion of > 40% diameter stenosis remaining proximal or distal to the target site after the planned intervention.
- •4. Previous placement of any stent at the target lesion and/or within 10 mm of the target lesion.
- •5. Lesion with a significant side branch (branch diameter >2 mm) that would be covered by stenting
- •6. Total occlusion or TIMI 0 coronary flow in the target vessel.
- •7. Left Main coronary artery disease (stenosis >50%)
- •8. The proximal target vessel or target lesion is severely calcified by visual assessment.
- •9. Aorto-ostial location, unprotected left main lesion location, or a lesion within 5 mm of the origin of the LAD or LCX.
- •10. The patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
- •11. The patient suffered a stroke, transient ischemic neurological attack (TIA) or significant gastrointestinal (GI) bleed within the past 6 months
- •12. The patient has renal insufficiency as determined by a creatinine of > 2.0mg/dl or 180 µmol/l.
- •13. The target lesion, or the target vessel proximal to the target lesion contains thrombus
- •14. Documented left ventricular ejection fraction of =30%
- •15. The patient is a recipient of a heart transplant
- •16. The patient has extensive peripheral vascular disease that precludes safe 6 French sheath insertion or extreme angulations of the vessel at accesslocation (< 45 degrees)
- •17. The patient has other medical illness (i.e., cancer or congestive heart failure) that may cause the patient to be non-compliant with the protocol, confound the data interpretation or is associated with limited life expectancy (i.e., less than one year)
- •18. The patient is simultaneously participating in another investigational device or drug study.
研究者
相似试验
已完成
3 期
Clinical study to evaluate the efficacy and safety of immunoglobulin intravenous (human) 10% (NewGam) in Primary Immune ThrombocytopeniaISRCTN37539930Octapharma AG (Switzerland)95
已完成
1 期
A Phase I, randomized, open-label, active-controlled, three-way treatment trial assessing pharmacokinetics, bioavailability and safety of three doses of CAM2038 q1w (once-weekly) (buprenorphine FluidCrystal® injection depot), versus active comparators, intravenous and sublingual buprenorphine, in healthy volunteers under naltrexone blockageTreatment of opioid dependenceMental and Behavioural DisordersMental and behavioural disorders due to use of opioidsISRCTN41550730Camurus AB (Sweden)60
已完成
4 期
Immunotherapy with racotumomab plus best support treatment in comparison to best support treatment alone in advanced non-small cell lung cancer patientsCancerISRCTN47153584Recombio SL (Spain)1,082
已完成
1 期
CAM2038, pharmacokinetics (PK), bioavailability and safety in healthy volunteersISRCTN24987553Camurus AB (Sweden)57
已完成
不适用
Efficacy and safety of intravaginal application of SAM vaginal gel on suspicious cervical smear results and on CIN 1 and CIN 2 lesionsCervical intraepithelial neoplasiaISRCTN11009040Deflamed International s.r.o.216